背景:少涎腺起源的肿瘤并不常见,占上消化道所有恶性肿瘤的2-3%,占所有唾液腺肿瘤的9-23%。这项研究的目的是报告人口统计学特征,网站,在多学科头颈部团队的大学医院诊断和治疗的口腔和口咽小涎腺肿瘤的组织学类型以及治疗和结局。
方法:在2000年7月30日至2021年9月30日期间接受口咽和口腔小涎腺癌诊断的患者队列中进行了一项单中心回顾性观察研究。收集纳入患者的以下数据:年龄,性别,烟雾史,酒精消费,既往病史,合并症,肿瘤的解剖位置,组织病理学,分期,管理,和结果。
结果:共30例(女性16例,对14例男性)的口腔和口咽小唾液腺肿瘤进行了回顾。最常见的组织型是多形性腺癌(12例)。大多数患者在诊断时表现为低阶段,66,66%的人群在诊断时被分类为I期或II期。总的来说,30名患者中有29名患者受益于手术方法作为第一治疗。在11名患者中,进行了辅助放疗,其中6例与化疗有关。5例进行不同时机的近距离放射治疗。复发率为26.66%。发现5年和10年的总体疾病特异性存活率分别为约81%和33%。
结论:手术仍被认为是治疗少涎腺肿瘤的金标准。放射治疗,尽管没有被认为是唾液恶性肿瘤的治愈性主要治疗方法,被广泛用作辅助治疗。
BACKGROUND: Tumors of minor salivary gland origin are uncommon lesions, representing 2-3 % of all malignant neoplasms of the upper aerodigestive tract and 9-23 % of all salivary gland tumors. The aim of this
study is to report the demographic features, sites, histological types and the management and outcomes of oral and oropharyngeal minor salivary gland tumors diagnosed and treated in a University Hospital with a multidisciplinary head and neck team.
METHODS: A single-center retrospective observational
study was conducted in a cohort of patients who received diagnosis of minor salivary gland carcinoma of oropharynx and oral cavity between July 30th 2000 and 30th September 2021. The following data of the included patients were collected: age, gender, smoke history, alcohol consumption, past medical history, comorbidities, anatomic location of the tumor, histopathology, staging, management, and outcomes.
RESULTS: A total of 30 cases (16 females, 14 males) of oral and oropharyngeal minor salivary gland tumors were reviewed. The most frequent histotype was polymorphous adenocarcinoma (12 patients). The majority of patients presented with low stage at diagnosis, with 66,66 % of the population classified as stage I or II at diagnosis. On the whole, 29 patients out of 30 benefitted from a surgical approach as first treatment. In 11 patients, adjuvant radiotherapy was performed and in 6 cases it was associated with chemotherapy. Brachytherapy with different timing was performed in 5 cases. The recurrence rate was 26.66 %. Overall disease specific survival at five and ten years was found to be approximately 81 % and 33 % respectively.
CONCLUSIONS: Surgery is still considered to be the gold standard of the treatment of minor salivary gland tumors. Radiation therapy, in spite of not being considered as a curative primary treatment for salivary malignancies, is extensively used as an adjuvant treatment.